DOCSLIB.ORG

Fentanyl Transdermal Patch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fentanyl Transdermal Patch Commissioning Support Fentanyl Transdermal Patch For the treatment of chronic intractable non-cancer pain Committee’s Verdict: CATEGORY B (Q4) Category B: Suitable for restricted prescribing under defined conditions (The committee did not consider guidance for the use of transdermal fentanyl for cancer-related pain because this was considered to be restricted to specialist care) Commissioning and prescribing considerations When commissioning a pain management service, commissioners should consider specifying criteria for patients who may need to use patches for analgesia, for example: o patients who cannot tolerate tablet formulations, or have difficulty swallowing (although liquid formulations and subcutaneous morphine may be suitable for some of these patients) o patients with mental health problems o patients with compliance issues or for those who are socially isolated with limited access to care Fentanyl should be initiated by a specialist or a specialist pain management service, given the range of alternative treatments available for the management of chronic non-cancer pain. Continued prescribing can then occur in primary care. Patients receiving fentanyl patches should be assessed frequently e.g. after two weeks, for the efficacy of the treatment, improvements in functional status, compliance and tolerability of side effects. Q4 rating: The evidence for the efficacy of fentanyl transdermal patches (TDF) in cancer- and non-cancer pain was relatively weak, based on five open-label trials that compared TDF with morphine sustained-release Q2 Q1 (SR) and one double-blind, placebo-controlled trial. Overall, TDF was higher place higher place shown to be as effective as morphine SR, and more effective than weaker evidence stronger evidence placebo. However, the subjective nature of the outcome measures and the open-label design made the trials subject to potential bias. The cost of TDF compared with oral morphine gives it a low place in therapy. Q4 Q3 lower place lower place The Q rating relates to the drug’s position on the effectiveness indicator weaker evidence stronger evidence grid. The strength of the evidence is determined by the quality and quantity of studies that show significant efficacy of the drug compared with placebo or Place in therapy in primary care alternative therapy. Its place in therapy in primary care takes into account safety Strength of evidence for efficacy and practical aspects of using the drug in primary care, alternative options, relevant NICE guidance, and the need for secondary care input. MTRAC reviewed transdermal fentanyl because of the potential for its prescribing to increase in primary care Description of technology malignant pain although their use has been controversial because repeated administration may The fentanyl transdermal patch was first launched in cause dependence and tolerance. the 1990’s. Fentanyl is a strong opioid analgesic, and is a schedule 2 controlled drug. The licensed NICE issued a draft Clinical Guideline for consultation indications reviewed were for the treatment of chronic in December 2011 on the use of strong opioids for 4 intractable cancer- and non-cancer pain in adults.1 pain management in palliative care. Oral morphine The Medicines and Healthcare Products Regulatory SR was recommended as first-line maintenance Agency (MHRA)2 warned that “fentanyl patches therapy. NICE recommended that transdermal should be used only in patients who have previously preparations may be considered for patients in whom tolerated opioids because of a risk of significant oral opioids are unsuitable and analgesic respiratory depression in opioid-naïve patients”. requirements are not changing rapidly, supported by specialist advice where needed. The final guideline is Background information expected in May 2012. The World Health Organisation (WHO) recommends Clinical efficacy the use of strong opioids (e.g. oxycodone or morphine) for the management of moderate to severe There were six randomised controlled trials with over pain due to cancer, at step three of the WHO three- 100 participants that evaluated TDF (Durogesic®, 25 step analgesic ladder.3 Strong opioids are also µg/hour initial dose) for the relief of chronic pain in 5-7 sometimes used to manage chronic, severe non- patients with cancer-related pain (3 trials, n = 202, January 2012 Page 1 of 2 108, 131), osteoarthritis (1 trial,8 n = 416), low back Additional information pain (1 trial,9 n= 680) or any chronic non-cancer pain (1 trial,10 n = 256). Fentanyl is also available in injectable, buccal, sublingual and nasal delivery formulations. For the Five of the trials5-7,9,10 were open-label and compared transdermal formulation, the initial starting dose is a 12 TDF with morphine SR (60 mg/day initial dose); the or 25 µg/hour patch, replaced every 72 hours. See the sixth trial was a double-blind trial that used a placebo 1 SPC for full details of doses and dose equivalents. patch as comparator in patients with osteoarthritis.8 The duration of the trials was variable: there were two At current prices, the costs of one year’s treatment are: cross-over trials with treatment arms lasting 2 or 4 o fentanyl transdermal patch (Matrifen) 25 to 100 weeks,5,10 three parallel trials lasting 4 to 6 weeks8-10 µg/hour, £310 to £993 and a parallel trial in patients with low back pain o fentanyl transdermal patch (Durogesic DTrans) lasting 13 months.9 25 to 100 µg/hour, £439 to £1,412 o morphine SR (Morphgesic) 10 to 100 mg twice The main outcome measures in the trials focussed on daily, £47 to £347 pain relief, tolerability and quality of life. (Other fentanyl transdermal patches are available) Results: Non-cancer pain Pain control: TDF treatment showed significantly Reference greater pain relief vs. a placebo patch in patients with 8 osteoarthritis. Compared with morphine SR, TDF 1. Janssen-Cilag Ltd. Durogesic DTrans 12/25/50/75/100 treatment showed significantly greater improvement in mcg/hr Transdermal Patch. SPC 2011 pain intensity in one trial,10 and was of similar efficacy http://www.medicines.org.uk/emc . in a second trial.9 One trial reported significantly 2. Medicines and Healthcare Products Regulatory Agency. greater use of rescue medication in TDF-treated Fentanyl patches: serious and fatal overdose from 10 dosing errors, accidental exposure, and inappropriate patients. use. Drug Safety Update. 2011. Quality of life: Two trials reported significantly greater http://www.mhra.gov.uk/home/groups/pl- improvements in some domains of the SF-36 for TDF- p/documents/publication/con025632.pdf <accessed treated patients than comparator-treated patients.8,10 12/2011> There were no significant differences in the third trial.9 3. World Health Organisation. WHO's pain ladder 2009. http://www.who.int/cancer/palliative/painladder/en/ Results: Cancer-related pain <accessed 7/2009> Pain relief: Three trials evaluated TDF vs. morphine 4. NICE clinical guideline draft for consultation. Opioids in SR in patients with cancer-related pain, and found no palliative care: safe and effective prescribing of strong significant differences between treatment groups for opioids for pain in palliative care of adults. NICE. 2011. any patient-rated pain measures. Two trials reported http://www.nice.org.uk/nicemedia/live/12953/57394/5739 greater use of immediate-release morphine as rescue 4.pdf <accessed 12/2011> 5. Ahmedzai S, Brooks D. Transdermal fentanyl versus medication in TDF-treated patients than in those 5,7 sustained-release oral morphine in cancer pain: receiving morphine SR. preference, efficacy, and quality of life. The TTS- Quality of life: There were no significant differences Fentanyl Comparative Trial Group. J Pain Symptom between treatment groups, in the two trials where Manage 1997;13:254-61. quality-of-life measures were reported.5,6 6. Mercadante S, Porzio G, Ferrera P et al. Sustained- release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008;12:1040-6. Adverse effects 7. van Seventer R, Smit J, Schipper R et al. Comparison of TTS-fentanyl with sustained-release oral morphine in Adverse events commonly reported in the trials were the treatment of patients not using opioids for mild-to- those usually associated with opioid use: nausea, moderate pain. Curr Med Res Opin 2003;19:457-69. vomiting, diarrhoea, constipation, dizziness and 8. Langford R, McKenna F, Ratcliffe S et al. Transdermal drowsiness or sedation. The incidences of adverse fentanyl for improvement of pain and functioning in effects varied across the trials and there were few osteoarthritis: a randomized, placebo-controlled trial. significant differences between the treatment groups. Arthritis Rheum 2006;54:1829-37. The incidence of constipation was significantly lower 9. Allan L, Richarz U, Simpson K et al. Transdermal with TDF than with morphine SR in three trials (p < fentanyl versus sustained release oral morphine in 7,9,10 strong-opioid naive patients with chronic low back pain. 0.001). See the Summary of Product Spine (Phila Pa 1976 ) 2005;30:2484-90. Characteristics (SPC) for full details of adverse 1 10. Allan L, Hays H, Jensen NH et al. Randomised events. crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-8. Launch date: 1995 Manufacturer: Janssen Cilag WARNING: This sheet should be read in conjunction with the Summary of Product Characteristics This guidance is based upon the published information available in English at the time the drug was considered. It remains open to review in the event of significant new evidence emerging. MTRAC can be contacted at the Dept. of Medicines Management, School of Pharmacy, Keele University, Keele, Staffs ST5 5BG Tel: 01782 734131 Email: [email protected] Web: www.mtrac.co.uk RELEVANT NICE GUIDANCE WAS NOT AVAILABLE AT THE TIME OF ISSUE OF THIS VERDICT Date: January 2012 ©Midlands Therapeutics Review & Advisory Committee .
Load more

Recommended publications
  • Analgesic Policy
    AMG 4pp cvr print 09 8/4/10 12:21 AM Page 1 Mid-Western Regional Hospitals Complex St. Camillus and St. Ita’s Hospitals ANALGESIC POLICY First Edition Issued 2009 AMG 4pp cvr print 09 8/4/10 12:21 AM Page 2 Pain is what the patient says it is AMG-Ch1 P3005 3/11/09 3:55 PM Page 1 CONTENTS page INTRODUCTION 3 1. ANALGESIA AND ADULT ACUTE AND CHRONIC PAIN 4 2. ANALGESIA AND PAEDIATRIC PAIN 31 3. ANALGESIA AND CANCER PAIN 57 4. ANALGESIA IN THE ELDERLY 67 5. ANALGESIA AND RENAL FAILURE 69 6. ANALGESIA AND LIVER FAILURE 76 1 AMG-Ch1 P3005 3/11/09 3:55 PM Page 2 CONTACTS Professor Dominic Harmon (Pain Medicine Consultant), bleep 236, ext 2774. Pain Medicine Registrar contact ext 2591 for bleep number. CNS in Pain bleep 330 or 428. Palliative Care Medical Team *7569 (Milford Hospice). CNS in Palliative Care bleeps 168, 167, 254. Pharmacy ext 2337. 2 AMG-Ch1 P3005 3/11/09 3:55 PM Page 3 INTRODUCTION ANALGESIC POLICY ‘Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’ [IASP Definition]. Tolerance to pain varies between individuals and can be affected by a number of factors. Factors that lower pain tolerance include insomnia, anxiety, fear, isolation, depression and boredom. Treatment of pain is dependent on its cause, type (musculoskeletal, visceral or neuropathic), duration (acute or chronic) and severity. Acute pain which is poorly managed initially can degenerate into chronic pain which is often more difficult to manage.
    [Show full text]
  • Neuropathic Pain
    www.bpac.org.nz keyword: neuropathic Pharmacological management of neuropathic pain Diagnosing neuropathic pain Pharmacological treatment Neuropathic pain is often described in the following A different analgesic ladder is used for neuropathic pain. terms: Adjuvants ▪ Burning Adjuvants can be continued through the pain ladder. ▪ Shooting Examples are capsaicin cream and local anaesthetic ▪ Stabbing gels. ▪ Lancinating Step one: Paracetamol It is classically associated with sensory changes to the Regular use of paracetamol is introduced first and is skin, either numbness or hypersensitivity (this may include recommended at every step of the pain ladder. allodynia – sensation of pain from light touch). There may also be visible autonomic changes (e.g. altered colouring or temperature of skin, sweating) or signs of motor damage Step two: Add a TCA (e.g. muscle wasting). Tricyclic antidepressants (TCAs) are usually prescribed at night as their sedative effects may assist sleep. Neuropathic pain may be caused by damage to central, Nortriptyline may be preferable due to its fewer adverse peripheral or autonomic nerves. effects, particularly in elderly people. Initial doses of TCAs are usually low, however doses can be increased to antidepressant level, if tolerated. BPJ | Issue 16 | 13 Neuropathic pain ladder STEP 1 STEP 2 STEP 3 Add or change to Add Anti-convulsant TCA Paracetamol Adjuvant treatment TCA dosing e.g. nortriptyline: titrate up from 10mg daily Step three: Add or change to an anticonvulsant until pain settles. Carbamazepine, sodium valproate and gabapentin are all Prescribe nortriptyline 10mg tablets. Increase the effective in treating neuropathic pain. dose as directed. Supply 70 tablets. Traditionally carbamazepine is the first choice but it Patient information: The dose may be increased as follows must be titrated very slowly to avoid side effects such as until the pain settles – Take one tablet (10mg) at night for nausea, vomiting and dizziness.
    [Show full text]
  • An Overview of Current Drug Advancement for Acute and Chronic Pain
    Open Access Austin Pain & Relief Mini Review An Overview of Current Drug Advancement for Acute and Chronic Pain Singh US* Department of Pharmaceutical and Biomedical Sciences, Abstract The University of Georgia, USA This short review focuses on medication for the management of pain along *Corresponding author: Uma S. Singh, Department with guidelines for the use of the prescribed medicines. WHO has suggested the of Pharmaceutical and Biomedical Sciences, College of pain ladder for the management of the acute and chronic pain. The use of the Pharmacy, The University of Georgia, Athens, GA 30602, non-opioid and opioids are reviewed. Also, the use of acetaminophen together USA with non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and COX-2 selective are described. Several other medicines which were originally invented Received: October 04, 2016; Accepted: November 03, for the cure of other diseases, but now they are well employed for pain treatment. 2016; Published: November 04, 2016 The anticonvulsant, gabapentin and pregabalin are in use for treatment of active pain. In the same way, for the treatment of osteoporosis, calcitonin was initially discovered but now it is in widely use for management of pain. The anesthetic ketamine is also used to treat pain. For the topical treatment, Lidocaine and capsaicin patches are being used to cure the localized pain. The applications of localized patches also help to avoid the maximum systemic adverse effect. Overall several drugs are being used for the treatment of the pain with the multi- component approaches for the acute and chronic pain relief. Keywords: Pain management; Opioids; Pain ladder; Analgesics Introduction start the oral administration of the drug with Non-Steroidal Anti- Inflammatory Drugs (NSAIDS) including COX-2 inhibitors for pain It is always a challenging task for a medical practitioner to relief [7].
    [Show full text]
  • Chronic Pain Ladder
    PAIN LADDER - CHRONIC PAIN Pain treatment pathway for non-cancer chronic pain ≥ 3 months duration in adults in primary care1,2,3,4 Key Principles • Consider early referral to West Suffolk Pain Service Single Point of Access in patients with excessive, uncontrolled or rapid escalating opioid requirements, and/or significant pain preventing sleep, function or work, or causing distress • Progressing through the steps below does not guarantee increased benefit or better pain relief. Medication does not always work; stop medicines that are not working. • 3-monthly medication reviews are recommended for all patients taking regular analgesics; prioritise Polypharmacy Medication Reviews for patients taking opioids or gabapentinoids STEP 1 Assessment and non pharmacological strategies • Exclude red flags. Assess pain/impact and yellow flags • Consider possibility of neuropathic/mixed pain: neuropathic pain ladder • Establish expectations and agreed goals • Discuss non pharmacological strategies and provide signposting information • Consider referral to: Wellbeing Service, physiotherapy, gentle exercise/weight loss programmes or TENS STEP 2 Paracetamol oral/rectal 1g qds (1g tds if < 50 kg, malnourished, renal or hepatic impairment) Paracetamol alone is not recommended management for low back pain 3 + / OR Ibuprofen oral 400 mg tds /topical 5% gel tds OR Naproxen oral 250-500 mg bd NSAID at lowest effective dose for shortest period. Consider a PPI. Consider possibility of neuropathic/mixed pain; refer to neuropathic pain ladder Ineffective or not tolerated: STOP Partially effective: consider adding STEP 3 Codeine oral 15-60 mg qds Avoid if breast feeding or if patient has experienced excessive response to codeine previously* OR Tramadol oral 50-100 mg qds OR Meptazinol oral 200 mg 3-6 hourly Consider referral to West Suffolk Pain Service Single Point of Access.
    [Show full text]
  • Stanford Acute Pain Management Resident Rotation Syllabus Version 2019-2020 Updated February 19, 2019 Table of Contents
    Stanford Acute Pain Management Resident Rotation Syllabus Version 2019-2020 Updated February 19, 2019 http://paincenter.stanford.edu Table of Contents PAIN MANAGEMENT FACULTY ........................................................................................................................ 2 GOALS AND OBJECTIVES ................................................................................................................................ 2 ADVERSE EFFECTS OF PERIOPERATIVE PAIN ........................................................................................... 5 OPIOIDS ............................................................................................................................................................. 7 NEURAXIAL ANALGESIA ................................................................................................................................. 15 REGIONAL ANESTHESIA AND PERIPHERAL NERVE CATHETERS .......................................................... 23 ADJUVANTS ..................................................................................................................................................... 30 OPIATE TOLERANT PATIENTS ....................................................................................................................... 40 CANCER PAIN .................................................................................................................................................. 37 ACUPUNCTURE AND PAIN MANAGEMENT ..................................................................................................
    [Show full text]
  • Analgesic Ladder for In-Patient
    ANALGESIC LADDER FOR IN‐PATIENT USE SEVERE MODERATE Oral intake MILD – constant Regular PARACETAMOL 1g qds MILD – intermittent Regular PARACETAMOL 1g qds + Regular PARACETAMOL 1g qds (oral or PR) Regular NSAID* (oral or PR) + (IBUPROFEN 400mg tds) + Regular NSAID* + prn PARACETAMOL 1g qds PRN NSAID* (oral IBUPROFEN 400mg tds or if unable to prn MORPHINE (Oramorph) 10mg every (oral or PR) (oral IBUPROFEN 400mg tds) tolerate oral medications PR DICLOFENAC two hours 50mg tds) No oral intake + Regular PR PARACETAMOL 1g qds Regular CODEINE PHOSPHATE§ + 30 to 60mg qds Regular NSAID* (PR DICLOFENAC 50mg tds) + Paracetamol and codeine can be prescribed IV MORPHINE protocol as co‐codamol 30/500 OR TWO tablets up to FOUR times a day; (via Acute Pain Team) Patient‐Controlled † ensure paracetamol alone is not also Analgesia / Epidural analgesia charted as this can lead to overdose. Additional Notes: *NSAID §Codeine phosphate Pain not controlled by pain ladder – contact Acute Pain Team. Please ensure that the pain Stop if regular NSAIDs give no benefit • Avoid with bowel surgery patients ladder has been used and medications given prior to contacting the service. Contra‐indications • Avoid if severe constipation Tramadol 50 to • History of hypersensitivity to aspirin/NSAIDs 100mg qds is alternative • Active GI ulceration or bleeding • May be added as “regular” in severe pain Prescribe anti‐emetic e.g. cyclizine 50mg tds • Severe heart failure, hepatic failure & renal failure †The IV morphine protocol or Patient‐Controlled • Coagulopathy Analgesia should
    [Show full text]
  • Pharmacology of Select Narcotic Analgesics
    ORIGINAL PAPER Adv Sci Med 2016; 1(4): 27-32 Pharmacology of select narcotic analgesics 1 1 Ewa Zieliński ABCDEF, Kinga Grobelska ABCDEF , 1 Department of Emergency Medicine and Disaster Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland Received: August 14.2016; Accepted: September 12.2016 Abstract Pain accompanies a human being from his birth until his death. It is associated with an unpleasant experience. There is a group of patients who can feel severe pain. In the 21st century no man should feel the pain connected with a disease process. Administration of opioids is the most effective method of relieving pain. The World Health Organization introduced rules for the treatment of pain based on the analge- sic ladder, starting from non-opioid analgesics up to strong opioids. The division of opioids is based on their affinity for opioid receptors, which are located in different parts of the body. Morphine is the commonest analgesic drug used in emergency medicine. Acute pain caused by trauma, acute cardiac incidents and chronic pain are main recommendations on the morphine application. Adverse side effects of morphine include respiratory depression, which can lead to acute respiratory failure. Keywords: pain, opioids, morphine, respiratory depression, analgesic ladder Introduction Mechanism of action All substances derived by chemical means from Pharmacologic effect of opioids closely associ- the sap of underripe poppy heads of the opium poppy ates with existence of specialised protein structures called Papaver somniferum are called opiates. Opioids are classi- receptors. The task of a receptor is to receive and trans- fied as narcotic analgesics.
    [Show full text]
  • Presentation: Codeine Has Little Role in Pain Management So What Do I Use
    Codeine has little role in pain management so what do I use now? Tony Hall Clinical Pharmacist, Advanced Senior Lecturer Gold Coast Interdisciplinary School of Clinical sciences, Persistent Pain Centre Faculty of Health, QUT DECLARATION OF CONFLICT OF INTEREST • Although I work for Queensland Health this presentation in no way indicates their support. The comments I make are my own, made as a clinical pharmacist academic. • I do not represent either The Pharmacy Guild or Pharmaceutical Society of Australia • I am a member of the Society of Hospital Pharmacists of Australia who support codeine rescheduling • I have received no payments from any Pharmaceutical Company regarding this work. • I have received no research grants from any Pharmaceutical Company Pharmacogenetics Link to induction of severe respiratory depression in children with CYP2D6 ultra- metaboliser genotype and in children (younger than18years) with Obstructive Sleep Apnoea having a tonsillectomy and adenoidectomy. Incidence of the CYP 2D6 enzyme genotypes among different ethnic populations Phenotype % % % % Caucasian Horn of Asian Hispanic Africa (Ethiopia, Somalia, Eritrea) Poor Metaboliser 3-10 1.8-8.1 0-1.2 2.2-6.6 (PM) Intermediate 1-2 N/A 51 N/A Metaboliser (IM) Ultrarapid/ 0.8-4.3 29 0.9 1-7 extensive Metaboliser (EM) N/A – not available Analgesic Efficacy Lack of evidence for efficacy at any dose <15mg Efficacy in Acute Pain • Oral codeine in a single dose of 60mg is not very effective in post operative setting (Derry 2010 Cochrane evaluation of 35 RCTS [n= 2475]) Effective for some individuals but does not compare favourably with alternatives e.g.
    [Show full text]
  • Taking Painkillers After Your Surgery
    Taking painkillers after your surgery This leaflet aims to answer your questions about taking painkillers after surgery. Inside each box of painkillers there should be an information leaflet from the manufacturer, specific to that medicine. Please make sure that you read these leaflets alongside this one. If you have any questions about your painkillers or any other medicines, please contact your local pharmacist (chemist) or GP for advice. Alternatively you can call our Pharmacy Medicines Helpline (contact details are at the end of this leaflet). Why do I need painkillers? Painkillers provide relief from pain. They can help you to feel more comfortable and can speed up the recovery process. Do I need to take more than one type of painkiller? One type of painkiller may not be enough to control your pain, so you might need to take two or more types of painkiller at the same time. The painkillers work in different ways so taking them together will help to control your pain better and minimise side effects. Four types of painkillers are commonly recommended after surgery: • paracetamol • non-steroidal anti-inflammatory drugs (such as ibuprofen or naproxen) • weak opioids (such as dihydrocodeine or codeine) • strong opioids (such as morphine or oxycodone). These are used in different combinations depending on how much pain you are in, and what painkillers suit you. The different combinations address different levels of pain. Some people find it useful to see these as steps on a ladder (see Figure 1). Paracetamol and non-steroidal anti-inflammatory drugs work differently, so can be taken at the same time.
    [Show full text]
  • Assessment and Management of Pain in the Elderly
    May 2007 Assessment and Management of Pain in the Elderly Self-directed learning package for nurses in long-term care. Supporting Implementation of the RNAO BPG Assessment and Management of Pain 1 Acknowledgement The Registered Nurses’ Association of Ontario (RNAO) and the Nursing Best Practice Guidelines Program would like to acknowledge the following individuals and organizations for their contribution to the development of the educational resource, Assessment and Management of Pain in the Elderly: Self-directed learning package for nurses in long-term care. • The RNAO Assessment and Management of Pain development and revision panel that developed the guideline on which this resource is based. • Sameer Kapadia B.Sc. Phm Clinical Pharmacist, Pulse Rx LTC Pharmacy, for the Dr.s Paul and John Rekai Centres. Disclaimer While every effort has been made to ensure the accuracy of the contents at their time of publication, neither the authors nor RNAO accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omissions in the contents of this work. Reference within this document to specific products or pharmaceuticals as examples does not imply endorsement of any of these products. Copyright With the exception of those portions of this document for which a specific prohibition or limitation against copying appears, the balance of this document may be produced, reproduced and published in its entirety, in any form, including in electronic form, for educational or non-commercial purposes, with the proviso that the content cannot be modified in any way. RNAO’s written permission must be sought for any adaptation of the content.
    [Show full text]
  • Drugs Used in Management of Pain
    #5 Drugs used in management of pain Objectives: Revise how pain is perceived and modulated, emphasizing on neurotransmitters, receptors, channels involved. Classify drugs used in management of pain. Expand on pharmacology of opiates, patterns of classification, mechanism of action, indications, ADR,…etc. detailing on morphine as an example. Compare in brief actions and indications of other opiate agonists and antagonists. Mind Map Anxiolytics • 1st class of drugs used. • Prevent the formation of the nociceptive Neuroleptic mediators. • Decrease opioid use by 30%. • Neither cause tolerance or dependence. Antidepressants • Has a ceiling effect to analgesia. Antiepileptics NSAIDs modify the perception of pain and remove the concomitants of pain such as anxiety, fear, depression. Drugs used in Adjuvant drugs management of pain RECEPTORS Opioids 1. Mu (µ). (G-protein 2. Kappa (ĸ). coupled r.) 3. Delta (δ). 4. ORL-1. Classification (According to) 1. Natural → Morphine 2. Semisynthetic → Heroin 3. Synthetic → Pethidine, Methadone, Their source TRAMADOL, Fentanyl Agonists Morphine, Codeine, Pethidine, Methadone agonistic/ antagonistic actions Mixed Antagonist Pentazocine Nalaxone, Naltraxone Their specificity of action on receptors • µ r. agonists → Morphine, codeine, heroin • agonist at k r. & antagonist at µ r. → Pentazocine 1 Drugs used in management of pain What is pain? The 5th vital sign suggests that assessment of pain should be as automatic as taking a client’s BP and pulse. Why should we treat pain? • Pain is a miserable experience •
    [Show full text]
  • Pharmacological Management of Cancer-Related Pain Eric E
    It is important that clinicians assess opioid responsiveness to determine whether adjuvant analgesics should play a role in the treatment plan. Photo courtesy of Lisa Scholder. Solid Stance. 16" × 24". Pharmacological Management of Cancer-Related Pain Eric E. Prommer, MD Background: Pain occurs in 50% of patients with cancer at the time of diagnosis, and nearly 80% of patients with advanced stage cancer have moderate to severe pain. Assessment of pain requires the health care profes- sional to measure pain intensity, delineate opioid responsiveness, and clarify the impact of pain on a patient’s psychological, social, spiritual, and existential domains. To this end, the World Health Organization (WHO) has developed a 3-step pain ladder to help the health care professional effectively manage pain, classifying pain intensity according to severity and recommending analgesic agents based on their strength. Methods: Health care professionals should follow the WHO guidelines to manage cancer-related pain in their patients. With regard to opioids, dosing, equianalgesic conversions, the management of adverse events, and the identification of new agents are discussed. Integrating adjuvant analgesics and interventional pain techniques into the management of cancer-related pain is also discussed. Results: The WHO analgesic ladder is an effective tool for managing cancer-related pain. Successful pain management in patients with cancer relies upon the health care professional to pay attention to detail, espe- cially during the introduction of new drugs and in identifying potential adverse events. Health care profes- sionals must assess opioid responsiveness to determine whether adjuvant analgesics should also play a role in a patient’s treatment plan.
    [Show full text]